MLICM
TSHA icon

Metropolitan Life Insurance Company (MetLife)’s Taysha Gene Therapies TSHA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,280
Closed -$84.8K – 2670
2021
Q4 		$84.8K Hold
7,280
– – ﹤0.01% 2564
2021
Q3 		$136K Buy
+7,280
New +$138K ﹤0.01% 2343

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TSHA Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Taysha Gene Therapies (TSHA) in Q1 2022, closing a stake of 7,280 shares — an estimated $84.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TSHA in Q3 2021 and held it in 2 quarters. The position peaked at $136K in Q3 2021. 71 funds tracked by Wall St. Rank hold TSHA as of Q1 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Taysha Gene Therapies position as of Q1 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 7,280 Taysha Gene Therapies shares in Q1 2022, an estimated $84.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Taysha Gene Therapies in Q3 2021 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Taysha Gene Therapies position peaked at $136K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.